Metformin has been reported to decrease aspartate aminotransferase and alanine transaminase levels in NAFLD patients, markers of liver injury, indicating that metformin alleviated hepatitis of NAFLD patients (Bugianesi et al., 2005; Zhou et al., 2018). Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.